ArticleFood & nutrition research2018
Nobiletin inhibits breast cancer via p38 mitogen-activated protein kinase, nuclear transcription factor-κB, and nuclear factor erythroid 2-related factor 2 pathways in MCF-7 cells.
Article in Food & nutrition research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- Animal- and Plant-Derived Protein Nanocarriers for the Delivery of Natural Compounds in Breast Cancer Chemoprevention.Molecules (Basel, Switzerland) · 2026Review
- Flavonoids as Modulators of the p53-Bcl-2 Axis in Cancer: Molecular Mechanisms and Therapeutic Implications.Pharmaceutics · 2026Review
- Nobiletin in cancer therapy: Emerging insights into multi-target mechanisms, overcoming drug resistance and therapeutic translation (Review).Oncology letters · 2026Review
- Nobiletin Ameliorates Doxorubicin-Induced Nephrotoxicity by Targeting Oxidative Stress, Inflammatory, and Apoptotic Pathways: CombinedACS omega · 2026Article
- Targeting the MAPK signaling pathway: implications and prospects of flavonoids in 3P medicine as modulators of cancer cell plasticity and therapeutic resistance in breast cancer patients.The EPMA journal · 2025Article
- Cytotoxic Effects ofACS omega · 2025Article
- Citrus flavonoids for overcoming breast cancer resistance to methotrexate: identification of potential targets of nobiletin and sinensetin.Discover oncology · 2025Article
- Tailoring carrier-free nanoparticles based on natural small molecule assembly for synergistic anti-tumor efficacy.Asian journal of pharmaceutical sciences · 2025Article
- Plant-Based Anticancer Compounds With a Focus on Breast Cancer.Cancer reports (Hoboken, N.J.) · 2024Review
- ExploringACS omega · 2024Article
- Article
- A comprehensive perspective of traditional Arabic or Islamic medicinal plants as an adjuvant therapy against COVID-19.Saudi journal of biological sciences · 2023Review
- Nrf2-mediated therapeutic effects of dietary flavones in different diseases.Frontiers in pharmacology · 2023Review
- Nobiletin resolves left ventricular and renal changes in 2K-1C hypertensive rats.Scientific reports · 2022Article
- Targeted Pyroptosis Is a Potential Therapeutic Strategy for Cancer.Journal of oncology · 2022Review
- Bcl-2 Modulation in p53 Signaling Pathway by Flavonoids: A Potential Strategy towards the Treatment of Cancer.International journal of molecular sciences · 2021Review
- Translating around the clock: Multi-level regulation of post-transcriptional processes by the circadian clock.Cellular signalling · 2021Review
- Food-Derived Pharmacological Modulators of the Nrf2/ARE Pathway: Their Role in the Treatment of Diseases.Molecules (Basel, Switzerland) · 2021Review
- The Application ofEvidence-based complementary and alternative medicine : eCAM · 2021Review
- Effects of glycyrrhizin on the pharmacokinetics of nobiletin in rats and its potential mechanism.Pharmaceutical biology · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBreast cancer is one of the most commonly diagnosed cancers in women, with a high mortality rate.
objectiveIn the present study, we evaluated the anticancer effect of nobiletin, a flavone glycoside, on the breast cancer cell line MCF-7.
resultCell viability and proliferation decreased and cell morphology changed from diamond to round after being treated with nobiletin. Nobiletin induced apoptosis of breast cancer MCF-7 cells via regulating the protein expression of Bax, Bcl-2, cleaved caspase-3, and p53. The expression of Bcl-2 decreased, while the expression of Bax and p53 increased in MCF-7 cells treated with nobiletin. Meanwhile, nobiletin inhibited cell migration by downregulating the protein expression of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). Moreover, phosphorylation of p38 was increased, and the translocation of p65 and nuclear factor erythroid 2-related factor 2 (Nrf2) to the nucleus was decreased, which suggested that the anticancer effects of nobiletin might at least partially rely on mediating the p38 mitogen-activated protein kinase, nuclear transcription factor-κB, and Nrf2 pathways in MCF-7 breast cancer cells. CONCLUSION AND RECOMMENDATION: Our data showed that nobiletin was a potential antitumor drug, and it provided some experimental basis for the clinical application of tumor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.